Keyphrases
Asthma Management
100%
Pranlukast
100%
Inhaled Corticosteroids
35%
Twice Daily
28%
Placebo
21%
Adult Patients
21%
Pediatric Patients
21%
Asthma
14%
Montelukast
14%
Adverse Events Profile
14%
Zafirlukast
14%
Mild-to-moderate Asthma
14%
Clinical Trials
7%
Clinically Significant
7%
Clinical Setting
7%
Therapeutic Potential
7%
Preventive Treatment
7%
High Dose
7%
Adverse Events
7%
Causal Relationship
7%
Cysteinyl Leukotrienes
7%
LTE4
7%
LTC4
7%
Leukotriene B4 (LTB4)
7%
Severe Asthma
7%
Monotherapy
7%
Prophylactic Treatment
7%
Once-daily
7%
Double-blind Trial
7%
Persistent Asthma
7%
Churg-Strauss Syndrome
7%
Orally Administered
7%
Competitive Antagonist
7%
Hepatic Function
7%
Peak Expiratory Flow Rate
7%
Bronchial Asthma
7%
Short-acting
7%
Gastrointestinal Events
7%
Inhaled Corticosteroid Therapy
7%
Bronchodilator
7%
Evening Peak
7%
Mild Persistent Asthma
7%
Oxatomide
7%
Severe Persistent Asthma
7%
Azelastine
7%
Event Function
7%
Tachyphylaxis
7%
Pharmacology, Toxicology and Pharmaceutical Science
Asthma
100%
Pranlukast
100%
Adverse Event
18%
Placebo
18%
Montelukast
12%
Zafirlukast
12%
Clinical Study
6%
Clinical Trial
6%
Peptidoleukotriene
6%
Moderate Persistent Asthma
6%
Churg Strauss Syndrome
6%
Competitive Antagonist
6%
Mild Persistent Asthma
6%
Bronchodilating Agent
6%
Severe Persistent Asthma
6%
Oxatomide
6%
Leukotriene C4
6%
Monotherapy
6%
Tachyphylaxis
6%
Azelastine
6%